Navigation Links
NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Date:10/6/2008

TOKYO and CHIPPENHAM, England, October 7 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC), announce results of two Phase II studies evaluating the efficacy, safety and tolerability of NVA237 presented at the annual congress of the European Respiratory Society (ERS) in Berlin, Germany. The new data show that NVA237 (glycopyrronium bromide), a novel inhaled long-acting muscarinic antagonist (LAMA), provides sustained 24-hour bronchodilation in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

NVA237 showed similar efficacy and duration of action to tiotropium with potentially a more rapid onset of action. In addition, studies lasting up to 28 days showed that NVA237 was safe and well tolerated with no clinically relevant cardiovascular findings.

NVA237 was licensed to Novartis by Sosei and Vectura in 2005 in a deal in which the two companies could receive up to US$ 375 million in milestones as well as royalties on product sales.

COPD affects 210 million people worldwide and is projected to be the third leading cause of death by 2030. It is a progressive lung disease with symptoms including chronic bronchitis and/or emphysema which slowly progress and eventually lead to a largely irreversible loss of lung function. While there is no cure, bronchodilators such as LAMAs make breathing easier by enlarging the patient's airways, and are recognized in international guidelines as first-line treatment for COPD.

One of the randomized, double-blind, placebo-controlled studies compared NVA237 (12.5, 25, 50 and 100microg once-daily) with placebo and open-label tiotropium. In the study involving 83 patients, all doses of NVA237 showed rapid onset of action and sustained 24-hour bronchodilation over the seven-day treatment period.

Clinically relevant improvements (i.e. >120mL more than placebo) in forced expiratory volume in one seco
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
2. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
3. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
4. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
5. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
10. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... WASHINGTON , July 31, 2014  Today,s ... relievers serves as an important reminder for consumers ... reinforces the importance of initiatives such as the ... Dose consumer education campaign. Formed in ... health, healthcare provider and consumer organizations dedicated to ...
(Date:7/31/2014)... 2014 De Pfizer Clinical Research Unit (PCRU) ... vrijwilligers van Japanse komaf voor medewerking aan klinisch onderzoek. ... is één van twee onderzoekseenheden van Pfizer , ... verbeteren door de ontdekking en ontwikkeling van nieuwe medicijnen. ... naar mannen en vrouwen van Japanse komaf – leeftijd ...
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
Breaking Medicine Technology:U.S. Health Coalition Calls for Continued Education on Acetaminophen, America's Most Common Drug Ingredient 2Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2
... and Chromium Histidinate Down-regulate Gene in Brain that ... and Efficacy of Nutrition 21,s Chromax Chromium PicolinatePURCHASE, ... NXXI ), the developer and marketer ... Diabetes Essentials brands, recently presented results of a ...
... First Pivotal Phase 3 Avanafil Study REVIVE (TA-301) is ... (Nasdaq: VVUS ), a biopharmaceutical company developing ... diabetes and sexual health, today announced that it has ... investigational drug, avanafil, in males with erectile dysfunction (ED). ...
Cached Medicine Technology:New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 2New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 3New Research Shows Nutrition 21's Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings 4VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 2VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 3
(Date:7/31/2014)... India (PRWEB) July 31, 2014 Reputation ... launched a new service named ‘Remove Bad Reviews’. The ... bad reviews are published on various review sites. ... the world of internet marketing, the sites that allow ... competitors in order to tailor the service. , ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 FITNESS SF, ... Francisco, announced that they will upgrade all locations to ... MyClub, and MoSo Pay. Motionsoft is a leading provider ... that automate member management and payments services for health ... relationship management suite, which FITNESS SF bundled with the ...
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... time after surgery may be reduced for patients taking ... new study. The study,s Irish researchers suspect that ... the amount of time surgical patients, wounds need to ... people who tend to have healing complications. "Statins ... in the world. While they are typically used to ...
(Date:7/31/2014)... Ethane Web Technologies, an ISO ... new service named ‘Java Development’. The service cost ... designed the service after doing a serious study ... service being provided by other web development companies. ... promise outstanding Java Development service. ...
Breaking Medicine News(10 mins):Health News:Reputation Management India Launches a New Service Called ‘Remove Bad Reviews’ 2Health News:FITNESS SF Upgrades Motionsoft Software to Include Entire Product Lineup: MoSo + MoSo Pay + MyClub 2Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2
... Julian ... searchbodydetox.com, a new informational Web site devoted to all aspects of whole body cleansing and ... Potomac, MD (Vocus) ... movement, is now a featured expert on searchbodydetox.com , a new informational Web site ...
... at Georgia State University have found that diets high in ... foods and beverages impaired the spatial memory of adult ... of Marise Parent, associate professor at Georgia State,s Neuroscience Institute ... a diet where fructose represented 60 percent of calories ingested ...
... , , MILWAUKEE, July 16 ... the nation in two different specialties, according to US News and ... same publication, St. Luke,s and Aurora Sinai Medical Center were recognized by ... , , (Logo: ...
... SWITZERLAND, July 16 /PRNewswire-FirstCall/ - BELLUS Health (International) Limited, ... Health, TSX: BLU), today announced that the Italian Ministry ... for VIVIMIND(TM) (homotaurine) as a food supplement. A certificate ... of the product in that country. This certificate opens ...
... , PHILADELPHIA, July 16 On Wednesday, ... its second quarter financial results for the three months ended June ... released to the London Stock Exchange at approximately 7:00 AM ... the announcement, Andrew Witty, Chief Executive Officer, Julian Heslop, Chief Financial ...
... ... just launched on Monday. , ... (Vocus) July 16, 2009 -- The National Practice Transition Network (NPTN), created ... practice sales and appraisals, is the first membership-based, commission-free organization to offer such a menu ...
Cached Medicine News:Health News:Dr. Julian Whitaker Featured on Searchbodydetox.com 2Health News:Researchers find that eating high levels of fructose impairs memory in rats 2Health News:Aurora's Milwaukee Hospitals Recognized in US News and World Report 2Health News:VIVIMIND(TM) granted certificate of free sale as food supplement in Italy - Premarket notification filed in the U.S. 2Health News:VIVIMIND(TM) granted certificate of free sale as food supplement in Italy - Premarket notification filed in the U.S. 3Health News:National Practice Transition Network Launches as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company 2
A One Piece Support Garment - any length or size...
Body Suit w/Bra torso, Front Closure...
Gynecomastia Vest...
Ideal for breast compression and contouring breast cups....
Medicine Products: